<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842086</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-412-2055</org_study_id>
    <secondary_id>2016-001399-31</secondary_id>
    <nct_id>NCT02842086</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection</brief_title>
  <acronym>DISCOVER</acronym>
  <official_title>A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM)
      and transgender women (TGW) who have sex with men and who are administered daily
      emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate
      (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks
      of follow-up after randomization.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HIV-1 Infection Per 100 Person Years (PY)</measure>
    <time_frame>When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)</time_frame>
    <description>The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.
HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:
Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or
Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or
Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR &quot;≤ 200 mg/g&quot; category includes both participants with UP &lt; 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HIV-1 Infection Per 100 PY</measure>
    <time_frame>When all participants have 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 157 weeks)</time_frame>
    <description>The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.
HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:
Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or
Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or
Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 96</time_frame>
    <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 96</time_frame>
    <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 96</time_frame>
    <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 96</time_frame>
    <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by UP and UPCR Categories at Week 96 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 96</time_frame>
    <description>The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR &quot;≤ 200 mg/g&quot; category includes both participants with UP &lt; 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase</measure>
    <time_frame>Baseline, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality</measure>
    <time_frame>First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5399</enrollment>
  <condition>Pre-Exposure Prophylaxis of HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F/TAF+ F/TDF placebo for at least 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F/TDF+ F/TAF placebo for at least 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment in the open-label extension for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/TAF</intervention_name>
    <description>200/25 mg tablet administered orally once daily</description>
    <arm_group_label>F/TAF</arm_group_label>
    <arm_group_label>Open-label Extension</arm_group_label>
    <other_name>Descovy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/TDF</intervention_name>
    <description>200/300 mg tablet administered orally once daily</description>
    <arm_group_label>F/TDF</arm_group_label>
    <other_name>Truvada®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/TAF Placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>F/TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/TDF Placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>F/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must be at high risk of sexual acquisition of HIV

          -  HIV-1 negative status

          -  MSM and TGW (male at birth) who have at least one of the following:

               -  condomless anal intercourse with at least two unique male partners in the past 12
                  weeks (partners must be either HIV-infected or of unknown HIV status)

               -  documented history of syphilis in the past 24 weeks

               -  documented history of rectal gonorrhea or chlamydia in the past 24 weeks

          -  Adequate renal function: estimated glomerular filtration rate ≥ 60 mL/min according to
             the Cockcroft-Gault formula

          -  Adequate liver and hematologic function:

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper
                  limit of normal (ULN) and total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

               -  Absolute neutrophil count ≥ 1000/mm^3; platelets ≥ 75,000/mm^3; hemoglobin ≥ 10
                  g/dL

        Key Exclusion Criteria

          -  Grade 3 or Grade 4 proteinuria or glycosuria that is unexplained or not clinically
             manageable.

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Men and Transgender Women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8051</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2l 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hvidovre</city>
        <state>Region Hovedstaden</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus N</city>
        <state>Region Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <state>RegionH</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <state>Alpe Maritimes</state>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <state>Provence</state>
        <zip>13006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <state>Provence</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10777</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin 7</city>
        <state>Dublin</state>
        <zip>D07 A8NN</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Soho</city>
        <state>London</state>
        <zip>W1D 6AQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whitechapel</city>
        <state>London</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH3 9HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <state>Sussex</state>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE18 4QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>WC1E 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M13 0FH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hare B. The Phase 3 DISCOVER Study: Daily F/TAF or F/TDF for HIV Preexposure Prophylaxis [Presentation]. Conference on Retroviruses and Opportunistic Infections (CROI); 2019 04-07 March; Seattle, WA.</citation>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <results_first_submitted>January 29, 2020</results_first_submitted>
  <results_first_submitted_qc>March 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2020</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02842086/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02842086/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in the United States, Canada, and the European Union. The first participant was screened on 02 September 2016. The data cut date for the end of blinded treatment phase was 12 December 2019.</recruitment_details>
      <pre_assignment_details>5857 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Descovy (DVY)</title>
          <description>Blinded Phase: Descovy (DVY; emtricitabine/tenofovir alafenamide [F/TAF] 200/25 mg) fixed-dose combination (FDC) tablet plus placebo-to-match Truvada (TVD) (emtricitabine/tenofovir disoproxil fumarate [F/TDF] 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Truvada (TVD)</title>
          <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2700"/>
                <participants group_id="P2" count="2699"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2156"/>
                <participants group_id="P2" count="2206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="544"/>
                <participants group_id="P2" count="493"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still in Double-Blind Phase</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="236"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HIV-1 Infection</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>Descovy (DVY)</title>
          <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Truvada (TVD)</title>
          <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2694"/>
            <count group_id="B2" value="2693"/>
            <count group_id="B3" value="5387"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="10.6"/>
                    <measurement group_id="B2" value="36" spread="10.7"/>
                    <measurement group_id="B3" value="36" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Transgender Women</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Reported data indicates sex at birth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2694"/>
                    <measurement group_id="B2" value="2693"/>
                    <measurement group_id="B3" value="5387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/Mixed Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2264"/>
                    <measurement group_id="B2" value="2247"/>
                    <measurement group_id="B3" value="4511"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other (Nonblack)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="635"/>
                    <measurement group_id="B2" value="683"/>
                    <measurement group_id="B3" value="1318"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2058"/>
                    <measurement group_id="B2" value="2008"/>
                    <measurement group_id="B3" value="4066"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1591"/>
                    <measurement group_id="B2" value="1629"/>
                    <measurement group_id="B3" value="3220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hip Bone Mineral Density (BMD)</title>
          <population>Hip Dual-Energy X-ray Absorptiometry (DXA) Analysis Set included all DXA substudy participants who were randomized and received at least one dose of study drug, and had nonmissing hip BMD value for the baseline visit. Participants were grouped according to the treatment they actually received.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="191"/>
                    <count group_id="B2" value="185"/>
                    <count group_id="B3" value="376"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.030" spread="0.1553"/>
                    <measurement group_id="B2" value="1.021" spread="0.1322"/>
                    <measurement group_id="B3" value="1.025" spread="0.1443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spine BMD</title>
          <population>Spine DXA Analysis Set included all DXA substudy participants who were randomized and received at least one dose of study drug, and had nonmissing spine BMD value for the baseline visit. Participants were grouped according to the treatment they actually received.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="191"/>
                    <count group_id="B2" value="188"/>
                    <count group_id="B3" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.134" spread="0.1646"/>
                    <measurement group_id="B2" value="1.131" spread="0.1381"/>
                    <measurement group_id="B3" value="1.132" spread="0.1518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Beta-2 Microglobulin to Creatinine Ratio</title>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>µg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2677"/>
                    <count group_id="B2" value="2676"/>
                    <count group_id="B3" value="5353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204.3" spread="951.77"/>
                    <measurement group_id="B2" value="188.5" spread="1010.19"/>
                    <measurement group_id="B3" value="196.4" spread="981.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Retinol Binding Protein (RBP) to Creatinine Ratio</title>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>µg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2686"/>
                    <count group_id="B2" value="2686"/>
                    <count group_id="B3" value="5372"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148.8" spread="553.54"/>
                    <measurement group_id="B2" value="142.8" spread="256.64"/>
                    <measurement group_id="B3" value="145.8" spread="431.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories</title>
          <description>The UPCR was only calculated when corresponding urine protein (UP) ≥ 4.0 mg/dL. The UPCR &quot;≤ 200 mg/g&quot; category includes both participants with UP &lt; 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.</description>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2687"/>
                    <count group_id="B2" value="2682"/>
                    <count group_id="B3" value="5369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≤ 200 mg/g</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2662"/>
                    <measurement group_id="B2" value="2657"/>
                    <measurement group_id="B3" value="5319"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 200 mg/g</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2694"/>
                    <count group_id="B2" value="2693"/>
                    <count group_id="B3" value="5387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.96" spread="0.146"/>
                    <measurement group_id="B2" value="0.96" spread="0.148"/>
                    <measurement group_id="B3" value="0.96" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HIV-1 Infection Per 100 Person Years (PY)</title>
        <description>The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.
HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:
Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or
Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or
Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)</description>
        <time_frame>When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)</time_frame>
        <population>The Full Analysis Set included all participants who were randomized into the study, received at least 1 dose of study drug, were not HIV positive on Day 1, and had at least 1 postbaseline HIV laboratory assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HIV-1 Infection Per 100 Person Years (PY)</title>
          <description>The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.
HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:
Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or
Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or
Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)</description>
          <population>The Full Analysis Set included all participants who were randomized into the study, received at least 1 dose of study drug, were not HIV positive on Day 1, and had at least 1 postbaseline HIV laboratory assessment.</population>
          <units>HIV-1 infections per 100 PY</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2670"/>
                <count group_id="O2" value="2665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.160" lower_limit="0.064" upper_limit="0.330"/>
                    <measurement group_id="O2" value="0.342" lower_limit="0.191" upper_limit="0.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Noninferiority was assessed using a 95.003% confidence interval (CI) constructed using a generalized model associated with a Poisson distribution and logarithmic link with the treatment group being the main effect and with a noninferiority margin of 1.62.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of DVY to TVD was to be concluded if the upper bound of the 2-sided 95.003% CI of the rate ratio (DVY group over TVD group) in the HIV infection incidence rate was less than 1.62.</non_inferiority_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.468</param_value>
            <ci_percent>95.003</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.191</ci_lower_limit>
            <ci_upper_limit>1.149</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Hip Dual-Energy X-ray Absorptiometry (DXA) Analysis Set included all DXA substudy participants who were randomized and received at least one dose of study drug, and had nonmissing hip BMD value for the baseline visit. Participants were grouped according to the treatment they actually received. Participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.</description>
          <population>Hip Dual-Energy X-ray Absorptiometry (DXA) Analysis Set included all DXA substudy participants who were randomized and received at least one dose of study drug, and had nonmissing hip BMD value for the baseline visit. Participants were grouped according to the treatment they actually received. Participants with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.218" spread="2.3668"/>
                    <measurement group_id="O2" value="-0.968" spread="2.4343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hip BMD results were compared between the 2 treatment groups using analysis of variance (ANOVA), which included baseline TVD for pre-exposure prophylaxis (PrEP) and treatment as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean (LSM)</param_type>
            <param_value>1.142</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.628</ci_lower_limit>
            <ci_upper_limit>1.655</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Spine DXA Analysis Set included all DXA substudy participants who were randomized and received at least one dose of study drug, and had nonmissing spine BMD value for the baseline visit. Participants were grouped according to the treatment they actually received. Participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.</description>
          <population>Spine DXA Analysis Set included all DXA substudy participants who were randomized and received at least one dose of study drug, and had nonmissing spine BMD value for the baseline visit. Participants were grouped according to the treatment they actually received. Participants with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.512" spread="2.9854"/>
                    <measurement group_id="O2" value="-1.061" spread="2.9382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spine BMD results were compared between the 2 treatment groups using ANOVA, which included baseline TVD for PrEP and treatment as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>1.567</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.913</ci_lower_limit>
            <ci_upper_limit>2.220</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug. Participants were grouped according to the treatment they actually received. Participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
          <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug. Participants were grouped according to the treatment they actually received. Participants with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2346"/>
                <count group_id="O2" value="2337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" lower_limit="-42.0" upper_limit="25.9"/>
                    <measurement group_id="O2" value="15.4" lower_limit="-22.9" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values were from the Van Elteren test stratified by baseline TVD for PrEP.</p_value_desc>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2360"/>
                <count group_id="O2" value="2354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-24.9" upper_limit="35.3"/>
                    <measurement group_id="O2" value="20.0" lower_limit="-13.0" upper_limit="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values were from the Van Elteren test stratified by baseline TVD for PrEP.</p_value_desc>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase</title>
        <description>The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR &quot;≤ 200 mg/g&quot; category includes both participants with UP &lt; 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase</title>
          <description>The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR &quot;≤ 200 mg/g&quot; category includes both participants with UP &lt; 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.</description>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2355"/>
                <count group_id="O2" value="2348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 48</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2318"/>
                    <measurement group_id="O2" value="2295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≤ 200 mg/g at Baseline; &gt; 200 mg/g at Week 48</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 200 mg/g at Baseline; ≤ 200 mg/g at Week 48</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 200 mg/g at Baseline; &gt; 200 mg/g at Week 48</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <p_value_desc>P-value for difference between treatment groups in distributions of UPCR ≤ 200 mg/g versus &gt; 200 mg/g was from the rank analysis of covariance adjusting for baseline category and baseline TVD for PrEP.</p_value_desc>
            <method>Rank analysis of covariance</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase</title>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase</title>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2370"/>
                <count group_id="O2" value="2368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.107"/>
                    <measurement group_id="O2" value="0.01" spread="0.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results were compared between the 2 treatment groups using the analysis of covariance (ANCOVA) model including baseline TVD for PrEP and treatment as fixed effects and baseline serum creatinine as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of HIV-1 Infection Per 100 PY</title>
        <description>The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.
HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:
Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or
Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or
Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)</description>
        <time_frame>When all participants have 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 157 weeks)</time_frame>
        <population>Participants in Full Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HIV-1 Infection Per 100 PY</title>
          <description>The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.
HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:
Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or
Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or
Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)</description>
          <population>Participants in Full Analysis Set were analyzed.</population>
          <units>HIV-1 infections per 100 PY</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2670"/>
                <count group_id="O2" value="2665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.159" lower_limit="0.069" upper_limit="0.313"/>
                    <measurement group_id="O2" value="0.297" lower_limit="0.166" upper_limit="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Noninferiority was assessed using a 95.003% CI constructed using a generalized model associated with a Poisson distribution and logarithmic link with the treatment group being the main effect and with a noninferiority margin of 1.62.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of DVY to TVD was to be concluded if the upper bound of the 2-sided 95.003% CI of the rate ratio (DVY group over TVD group) in the HIV infection incidence rate was less than 1.62.</non_inferiority_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.536</param_value>
            <ci_percent>95.003</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.227</ci_lower_limit>
            <ci_upper_limit>1.264</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.</description>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Participants in Hip DXA Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.</description>
          <population>Participants in Hip DXA Analysis Set with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.565" spread="2.9379"/>
                    <measurement group_id="O2" value="-1.048" spread="2.9277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hip BMD results were compared between the 2 treatment groups using ANOVA, which included baseline TVD for PrEP and treatment as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>1.567</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.896</ci_lower_limit>
            <ci_upper_limit>2.237</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.</description>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Participants in Spine DXA Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.</description>
          <population>Participants in Spine DXA Analysis Set with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.831" spread="3.4608"/>
                    <measurement group_id="O2" value="-1.426" spread="3.5508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spine BMD results were compared between the 2 treatment groups using ANOVA, which included baseline TVD for PrEP and treatment as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>2.253</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.437</ci_lower_limit>
            <ci_upper_limit>3.069</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2169"/>
                <count group_id="O2" value="2195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" lower_limit="-45.4" upper_limit="23.9"/>
                    <measurement group_id="O2" value="14.1" lower_limit="-26.2" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values were from the Van Elteren test stratified by baseline TVD for PrEP.</p_value_desc>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase</title>
        <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase</title>
          <description>Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.
For urine creatinine, value of &lt; 1 was handled as a missing value in its summary and the calculation of related ratios.</description>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2188"/>
                <count group_id="O2" value="2211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-27.1" upper_limit="35.7"/>
                    <measurement group_id="O2" value="21.4" lower_limit="-13.8" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values were from the Van Elteren test stratified by baseline TVD for PrEP.</p_value_desc>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by UP and UPCR Categories at Week 96 in the Blinded Phase</title>
        <description>The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR &quot;≤ 200 mg/g&quot; category includes both participants with UP &lt; 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.</description>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by UP and UPCR Categories at Week 96 in the Blinded Phase</title>
          <description>The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR &quot;≤ 200 mg/g&quot; category includes both participants with UP &lt; 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.</description>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2175"/>
                <count group_id="O2" value="2199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 96</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2134"/>
                    <measurement group_id="O2" value="2153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≤ 200 mg/g at Baseline; &gt; 200 mg/g at Week 96</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 200 mg/g at Baseline; ≤ 200 mg/g at Week 96</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 200 mg/g at Baseline; &gt; 200 mg/g at Week 96</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2163</p_value>
            <p_value_desc>P-value for difference between treatment groups in distributions of UPCR ≤ 200 mg/g versus &gt; 200 mg/g was from the rank analysis of covariance adjusting for baseline category and baseline TVD for PrEP.</p_value_desc>
            <method>Rank analysis of covariance</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase</title>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase</title>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2194"/>
                <count group_id="O2" value="2218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.114"/>
                    <measurement group_id="O2" value="0.03" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results were compared between the 2 treatment groups using the ANCOVA model including baseline TVD for PrEP and treatment as fixed effects and baseline serum creatinine as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</title>
        <time_frame>First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)</time_frame>
        <population>Participants in Safety Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</title>
          <population>Participants in Safety Analysis Set were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2694"/>
                <count group_id="O2" value="2693"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality</title>
        <time_frame>First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)</time_frame>
        <population>Participants in Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Descovy (DVY)</title>
            <description>Blinded Phase: DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Truvada (TVD)</title>
            <description>Blinded Phase: TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality</title>
          <population>Participants in Safety Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2672"/>
                <count group_id="O2" value="2665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1"/>
                    <measurement group_id="O2" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)</time_frame>
      <desc>The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Descovy (DVY)</title>
          <description>DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Truvada (TVD)</title>
          <description>TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pectus excavatum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Sickle cell disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular myasthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cyclic vomiting syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Enlarged uvula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Mesenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Rectal lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Treatment failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Eye infection gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Escherichia coli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Infective tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Large intestine infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Lymphogranuloma venereum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Meningitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Proctitis chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Reactive gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Scan myocardial perfusion abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Astrocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Oesophageal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Testicular seminoma (pure)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cerebral venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Alcohol use disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Vocal cord thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ligament operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2258" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="2229" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="479" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="451" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="890" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="902" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="399" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="402" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Oropharyngeal gonococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="871" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="838" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pharyngeal chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Proctitis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="805" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="797" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="413" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="392" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="402" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="346" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Urethritis chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="346" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="314" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Urethritis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="255" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" subjects_affected="554" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="548" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="2693"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="2694"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="2693"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

